Sarepta Therapeutics Off To A Strong Start With New Name And Data
This article was originally published in The Pink Sheet Daily
Executive Summary
The RNA drug-discovery company, formerly AVI BioPharma, is reinventing itself as an orphan disease drug specialist called Sarepta Therapeutics. With the release of positive Phase IIb data on its lead candidate for Duchenne muscular dystrophy, the transformation has gotten a big boost.